NCT02638142 Loop Diuretic Therapy in Acutely Decompensated Heart Failure
| NCT ID | NCT02638142 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Siena |
| Condition | Acute Heart Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 370 participants |
| Start Date | 2015-12 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 370 participants in total. It began in 2015-12 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
DiurHF is a prospective, multicenter, observational, study that compares continuous with intermittent infusion of furosemide in patients admitted with a diagnosis of ADHF. Previous pilot study design was planned to anticipate a larger multicenter trial able to definitively evaluate the optimal loop diuretic use strategy in patients with ADHF.
Eligibility Criteria
Inclusion Criteria: * Patients over 18 years; * Patients with diagnosis of ADHF(dyspnea, orthopnea, peripheral edema or major fatigue and at least two clinical signs including rales, hepatomegaly, pulmonary congestion on chest radiography, jugular vein dilatation, or a third heart sound); * Blood BNP \> 100 pg/mL; ADHF: Acute Decompensated Heart Failure; BNP: B-type Natriuretic Peptide; IV: IntraVenous; LVEF: Left Ventricular Ejection Fraction. Exclusion Criteria: * Patients who receive more than 40 mg of IV furosemide; * End-Stage renal disease or renal replacement therapy; * Recent myocardial infarction (within thirty days of screening); * Systolic blood pressure \< 80 mmHg; * Creatinine levels \> 4 mg/dL; * Patients affected by sepsis, liver diseases, inflammatory diseases or neoplastic diseases.
Contact & Investigator
Alberto Palazzuoli, MD
PRINCIPAL INVESTIGATOR
University of Siena
Frequently Asked Questions
Who can join the NCT02638142 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02638142 currently recruiting?
Yes, NCT02638142 is actively recruiting participants. Contact the research team at palazzuoli2@unisi.it for enrollment information.
Where is the NCT02638142 trial being conducted?
This trial is being conducted at Chioggia, Italy, Padova, Italy, Roma, Italy, Siena, Italy.
Who is sponsoring the NCT02638142 clinical trial?
NCT02638142 is sponsored by University of Siena. The principal investigator is Alberto Palazzuoli, MD at University of Siena. The trial plans to enroll 370 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.